Evaluation of cardiovascular risk in a lung cancer screening cohort
Thorax Sep 30, 2019
Ruparel M, Quaife SL, Dickson JL, et al. - Among lung cancer screening (LCS) participants in the Lung Screen Uptake Trial, researchers investigated the benefit of coronary artery calcification (CAC) and cardiovascular disease (CVD) risk evaluation in this cross-sectional analysis. Participants (n = 680) aged 60–75 years and were current and ex-smokers. The presence of CAC was noted in 421 (61.9%) and in 49 (7.2%), this was heavy. A QRISK2 ≥ 10% was seen in 668 (98%) of participants, and a positive link of QRISK2 with increasing CAC grade was evident. A history of statin use was not reported by 56.8% of those who qualified for statin primary prevention (QRISK2 ≥ 10%). The link of statin use with age, body mass index and history of hypertension and diabetes was revealed in the multivariate analysis. In all LCS participants, CVD risk evaluation may be done along with LCS, regardless of the presence of low-dose computed tomography-detected CAC.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins